Did Deepinder Goyal prove Temple is not a scam because it offers a 14-day return policy?

Temple offers a 14-day, no-questions-asked return policy, which even Apple does not offer in India.111

The 14-day no-questions-asked return window is reported consistently as Temple's stated policy across Indian business and technology outlets that covered the post. That part is well supported. The comparison to Apple is deliberately weaker: the assertion that Apple does not offer such a window in India appears only as Goyal's own claim and was not independently checked in the coverage we reviewed. So the policy is likely real, but the competitive framing attached to it is one person's say-so. Readers should treat the refund window as a customer-service fact and not let it borrow credibility from the comparison. This claim is central only in the sense that it anchors the post's central argument; the policy existing does not settle whether the argument built on it is sound.

Still open: The Apple comparison was not independently audited in the sources we reviewed.

Temple has already spent $30 million building the device, $20 million of which is Goyal's own money.511

Every major report repeats these figures, but they all trace back to the same origin: Goyal's post. Eight outlets carrying the same number is one source repeated, not eight independent confirmations. We found no filing, audited accounts or disclosure that would confirm either the total $30 million spend or the split between personal and company capital. That does not make the figures false. Founders routinely know their own spending better than anyone else. It does mean the number should be read as a claim from the founder, not as an audited fact, and it should not be used as evidence that the device works. Money spent is evidence of money spent.

Still open: No corporate filing or audited figure was located to confirm the split between personal and company investment.

Each of Temple's claims is easily verifiable by individuals and institutions, and the company stands by its science and methods.4789

The advertised core metrics, notably cerebral blood flow derived from a sensor sitting over the superficial temporal artery outside the skull, and a novel Entropy score, have no peer-reviewed or independent validation in anything we reviewed. Independent clinicians put the central objection plainly: light-based sensing reaches only 1-2 cm of depth and cannot substitute for perfusion imaging of brain blood flow, and there are no clinical outcome studies. Goyal himself said elsewhere that Temple is a fitness and wellness device rather than a medical device, and that research breakthroughs are still being validated and will be disclosed when available. That is a reasonable position to take. It is not compatible with telling readers the claims are already easily verifiable. The two statements cannot both be true in the same breath.

Still open: The company has said pre-prints and future independent studies are coming; at the time of writing none had been published in the coverage we reviewed.

Most wearable companies start with internal studies; Whoop shipped its band in 2015 and its first published validation followed a few years later.3

The sequence described is broadly accurate: Whoop brought its strap to market around 2015 and published validation research in later years, and starting with internal studies is standard in consumer wearables. So this point is not invented, and it is reasonable to say products can launch before their validation literature appears. The analogy is where the argument thins. Doctors responding to the post argued that Whoop validated parameters its hardware can actually measure, while Temple advertises brain blood flow from outside the skull. A precedent for launching early is not a precedent for advertising a metric the sensor cannot reach. Readers should weigh the industry norm as context and not as a defence of any particular measurement.

I left the Eternal CEO role to chase purpose with Temple.210

This is the least contested claim in the post. Multiple outlets report that Goyal stepped down as CEO of Eternal, Zomato's parent company, to build Temple full time, and that he now holds vice-chairman and non-executive director roles at Eternal. A change of that kind cannot be done quietly, and the coverage treats it as a matter of record. It is worth noting that this claim, though true, carries no weight on the question the post is really about. Leaving a job to build something shows commitment. It does not show that the thing works, and the post places it alongside the refund and spending arguments as if all three were evidence.

Employees bought into an earlier funding round and the round now being raised is mostly customers, which supposedly shows it is not a scam.12

This is asserted only by Goyal in the post, and we located no independent corporate filing or investor disclosure confirming who is on Temple's cap table or who is backing the current round. The claim also carries a hidden assumption: that sophisticated or repeat investors can see through a product and therefore validate it. That is not reliable. Investors back people and markets, and several well-funded products have turned out to be badly flawed. Even if the cap-table description is accurate, it would show that people with money believe in the venture, not that the sensors are accurate. We mark it unverifiable and low confidence because the evidence is thin and the inference is doing most of the work.

Still open: No cap table, funding filing or investor statement was located.

Implied: the doctors criticising Temple are spreading twisted facts and their criticism is baseless rage.269

The substantive criticism from Indian clinicians is methodological, not personal. It is that Temple's brain blood flow and Entropy claims lack independent, peer-reviewed validation and that the sensor sits over an artery outside the skull, which cannot measure cerebral blood flow the way perfusion imaging does. That is a legitimate objection anyone could make about any wearable. Presenting it as rage over twisted facts reframes a technical dispute as a temper problem. Goyal himself later apologised, saying he should not have bucketed all Indian doctors into one box and that his frustration was aimed at a few influencer doctors. That apology is the strongest evidence that the framing was unfair: the author of the post walked it back.